THE ROLE AND BIOMARKER VALUE OF IL-17 AND IL-23 CYTOKINES IN LABORATORY DIAGNOSIS OF AXIAL SPONDYLOARTHRITIS
Keywords:
axial spondyloarthritis, IL-17, IL-23, biomarkers, laboratory diagnosis, cytokines, inflammatory axis, Th17 cells, enthesitis, biologic therapiesAbstract
Axial spondyloarthritis (axSpA) is a chronic inflammatory rheumatic disease characterized by predominant involvement of the spine and sacroiliac joints. The disease is associated with inflammatory back pain, stiffness, enthesitis, and progressive structural changes including syndesmophyte formation and ankylosis. Recent studies highlight the important role of the IL-23/IL-17 inflammatory axis in the pathogenesis of axSpA.
Further research integrating cytokine profiling with genetic and microbiome factors may improve early detection and individualized treatment strategies in axial spondyloarthritis.
References
1. O’Rielly, D.D., Zhai, G. & Rahman, P. Expression and Metabolomic Profiling in Axial Spondyloarthritis. Curr Rheumatol Rep 20, 51 (2018). https://doi.org/10.1007/s11926-018-0756-y
2. Queiro R, Aurrecoechea E, Alonso Castro S, Villa Blanco I, Brandy-Garcia A, Linge R. Interleukin-17-targeted treatment in patients with spondyloarthritis and associated cardiometabolic risk profile. Front Immunol. 2023 Jul 18;14:1203372. doi: 10.3389/fimmu.2023.1203372. PMID: 37533855; PMCID: PMC10391638.
3. Kaltsonoudis E, Karagianni P, Memi T, Pelechas E. State-of-the-Art Review on the Treatment of Axial Spondyloarthritis. Med Sci (Basel). 2025 Mar 16;13(1):32. doi: 10.3390/medsci13010032. PMID: 40137452; PMCID: PMC11944150.
4. Tsukazaki H, Kaito T. The Role of the IL-23/IL-17 Pathway in the Pathogenesis of Spondyloarthritis. Int J Mol Sci. 2020 Sep 3;21(17):6401. doi: 10.3390/ijms21176401. PMID: 32899140; PMCID: PMC7504446.
5. Al-Ani, R. (2025). Assessment of serum interleukin-23 as a biomarker for diagnosis and disease activity evaluation in ankylosing spondylitis patients. Asian Journal of Basic and Applied Sciences. https://journal.uokufa.edu.iq/index.php/ajb/article/view/20076
6. Baeten, D., & Sieper, J. (2023). Have therapeutics enhanced our knowledge of axial spondyloarthritis pathogenesis? Current Rheumatology Reports, 25(2), 43–51. https://doi.org/10.1007/s11926-023-01097-7
7. Ceribelli, A., Motta, F., Vecellio, M., Isailovic, N., Ciccia, F., & Selmi, C. (2021). Clinical trials supporting the role of the IL-17/IL-23 axis in axial spondyloarthritis. Frontiers in Immunology, 12, Article 622770. https://doi.org/10.3389/fimmu.2021.622770
8. Chen, W., & Lin, J. (2011). Increased serum IL-17 and IL-23 in the patients with ankylosing spondylitis. Clinical Rheumatology, 30(2), 269–273. https://doi.org/10.1007/s10067-010-1647-4
9. Macleod, T., Bridgewood, C., & McGonagle, D. (2023). Role of neutrophil interleukin-23 in spondyloarthropathy spectrum disorders. The Lancet Rheumatology, 5(1), e47–e57. https://doi.org/10.1016/S2665-9913(22)00334-4
